tbuckley/cabot-search huggingface dataset:
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study
Authors: Gi-Ae Kim, Seogsong Jeong, Heejoon Jang, Dong Hyeon Lee, Sae Kyung Joo, Won Kim
Journal: Liver Cancer (2023)

&lt;b&gt;&lt;i&gt;Introduction:&lt;/i&gt;&lt;/b&gt; This study aimed to investigate the liver-related outcomes of newly suggested metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD with increased alcohol intake (MetALD), as well as alcohol-associated liver disease (ALD). &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; From a National Health Insurance Service Health Screening Cohort, we included 369,094 participants who underwent health checkups between 2009 and 2010 in South Korea. Steatotic liver disease (SLD) was defined as a fatty liver index ≥60. The risk of primary liver cancer (PLCa), hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), incident cirrhosis, and decompensated cirrhosis was compared with no SLD. The subdistribution hazard ratio (SHR) was calculated using the Fine-Gray model regarding competing risks. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; A total of 3,232 participants (0.9%) developed PLCa during the median follow-up of 3,227,176 person-years: 0.5% with no SLD, 1.1% with MASLD, 1.3% with MetALD, and 1.9% with ALD. Competing risk analysis revealed that compared with no SLD, MASLD (SHR: 1.65; 95% CI: 1.44−1.88), MetALD (SHR: 1.87; 95% CI: 1.52−2.29), and ALD (SHR: 1.86; 95% CI: 1.39−2.49) were associated with an increased risk of PLCa. MASLD (SHR: 1.96; 95% CI: 1.67−2.31), MetALD (SHR: 2.23; 95% CI: 1.75−2.84), and ALD (SHR: 2.34; 95% CI: 1.67−3.29) were associated with a higher risk of HCC. No significant difference was observed in the risk of iCCA. The risk of incident cirrhosis and decompensated cirrhosis increased in the order of no SLD, MASLD, MetALD, and ALD. &lt;b&gt;&lt;i&gt;Conclusion:&lt;/i&gt;&lt;/b&gt; MASLD, MetALD, and ALD have an increased risk of PLCa, HCC, incident cirrhosis, and decompensated cirrhosis but not iCCA. These findings may serve as a robust ground for the prognostic value of the newly suggested MASLD and MetALD.
Epicardial placement of human MSC-loaded fibrin sealant films for heart failure: Preclinical efficacy and mechanistic data
Authors: Laura Fields, Tomoya Ito, Kazuya Kobayashi, Yuki Ichihara, Mihai-Nicolae Podaru, Mohsin Hussain, Kizuku Yamashita, Vanessa Machado, Fiona Lewis-McDougall, Ken Suzuki
Journal: Molecular Therapy (2023)

(Molecular Therapy 29, 2554–2570; August 2021) In the originally published version of this article, there were errors in the cell culture images of Figure S8A. The corrected version is shown below. This correction does not alter the graph, result, or conclusion of the study. The authors would like to apologize for any inconvenience caused. Epicardial placement of human MSC-loaded fibrin sealant films for heart failure: Preclinical efficacy and mechanistic dataFields et al.Molecular TherapyApril 19, 2021In BriefThis study reports pre-clinical proof of concept of human-derived MSC-dressings (epicardial placement of fibrin sealant films incorporating human amniotic membrane-derived MSCs) as an advanced cell-based therapy for heart failure. Transplanted MSCs augment cardiac M2-like macrophages via PGE2, CCL2, and TGF-β1, establishing sustainable myocardial repair through M2-like macrophages’ secretome (secondary paracrine effect). Full-Text PDF Open Access
Identification of pan-cancer/testis genes and validation of therapeutic targeting in triple-negative breast cancer: Lin28a-based and Siglece-based vaccination induces antitumor immunity and inhibits metastasis
Authors: Jason A Carter, Bharati Matta, Jenna Battaglia, Carter Somerville, Benjamin D Harris, Margaret LaPan, Gurinder S Atwal, Betsy J Barnes
Journal: Journal for ImmunoTherapy of Cancer (2023)

Background Cancer–testis (CT) genes are targets for tumor antigen-specific immunotherapy given that their expression is normally restricted to the immune-privileged testis in healthy individuals with aberrant expression in tumor tissues. While they represent targetable germ tissue antigens and play important functional roles in tumorigenesis, there is currently no standardized approach for identifying clinically relevant CT genes. Optimized algorithms and validated methods for accurate prediction of reliable CT antigens (CTAs) with high immunogenicity are also lacking. Methods Sequencing data from the Genotype-Tissue Expression (GTEx) and The Genomic Data Commons (GDC) databases was used for the development of a bioinformatic pipeline to identify CT exclusive genes. A CT germness score was calculated based on the number of CT genes expressed within a tumor type and their degree of expression. The impact of tumor germness on clinical outcome was evaluated using healthy GTEx and GDC tumor samples. We then used a triple-negative breast cancer mouse model to develop and test an algorithm that predicts epitope immunogenicity based on the identification of germline sequences with strong major histocompatibility complex class I (MHCI) and MHCII binding affinities. Germline sequences for CT genes were synthesized as long synthetic peptide vaccines and tested in the 4T1 triple-negative model of invasive breast cancer with Poly(I:C) adjuvant. Vaccine immunogenicity was determined by flow cytometric analysis of in vitro and in vivo T-cell responses. Primary tumor growth and lung metastasis was evaluated by histopathology, flow cytometry and colony formation assay. Results We developed a new bioinformatic pipeline to reliably identify CT exclusive genes as immunogenic targets for immunotherapy. We identified CT genes that are exclusively expressed within the testis, lack detectable thymic expression, and are significantly expressed in multiple tumor types. High tumor germness correlated with tumor progression but not with tumor mutation burden, supporting CTAs as appealing targets in low mutation burden tumors. Importantly, tumor germness also correlated with markers of antitumor immunity. Vaccination of 4T1 tumor-bearing mice with Siglece and Lin28a antigens resulted in increased T-cell antitumor immunity and reduced primary tumor growth and lung metastases. Conclusion Our results present a novel strategy for the identification of highly immunogenic CTAs for the development of targeted vaccines that induce antitumor immunity and inhibit metastasis.
Association of indicators of extensive disease and rifampin-resistant tuberculosis treatment outcomes: an individual participant data meta-analysis
Authors: Jonathon R Campbell, Sarah K Brode, Pennan Barry, Mayara Lisboa Bastos, Maryline Bonnet, Lorenzo Guglielmetti, Russell Kempker, Dzmitry Klimuk, Rafael Laniado Laborín, Vladimir Milanov, Rupak Singla, Alena Skrahina, Anete Trajman, Tjip S van der Werf, Piret Viiklepp, Dick Menzies
Journal: Thorax (2023)

Background Indicators of extensive disease—acid fast bacilli (AFB) smear positivity and lung cavitation—have been inconsistently associated with clinical rifampin-resistant/multidrug-resistant tuberculosis (RR/MDR-TB) outcomes. We evaluated the association of these indicators with end-of-treatment outcomes. Methods We did an individual participant data meta-analysis of people treated for RR/MDR-TB with longer regimens with documented AFB smear and chest radiography findings. We compared people AFB smear-negative without cavities to people: (1) smear-negative with lung cavities; (2) smear-positive without lung cavities and (3) AFB smear-positive with lung cavities. Using multivariable logistic regression accounting for demographic, treatment and clinical factors, we calculated adjusted ORs (aOR) for any unfavourable outcome (death, lost to follow-up, failure/recurrence), and mortality and treatment failure/recurrence alone. Results We included 5596 participants; included participants significantly differed from excluded participants. Overall, 774 (13.8%) were AFB smear-negative without cavities, 647 (11.6%) only had cavities, 1424 (25.4%) were AFB smear-positive alone and 2751 (49.2%) were AFB smear-positive with cavities. The median age was 37 years (IQR: 28–47), 3580 (64%) were male and 686 (12.5%) had HIV. Compared with participants AFB smear-negative without cavities, aOR (95% CI) for any unfavourable outcome was 1.0 (0.8 to 1.4) for participants smear-negative with lung cavities, 1.2 (0.9 to 1.5) if smear-positive without cavities and 1.6 (1.3 to 2.0) if AFB smear-positive with lung cavities. Odds were only significantly increased for mortality (1.5, 95% CI 1.1 to 2.1) and failure/recurrence (2.2, 95% CI 1.5 to 3.3) among participants AFB smear-positive with lung cavities. Conclusion Only the combination of AFB smear-positivity and lung cavitation was associated with unfavourable outcomes, suggesting they may benefit from stronger regimens.
Arsenic Exposure and Epigenetic Aging: The Association with Cardiovascular Disease and All-Cause Mortality in the Strong Heart Study
Authors: Enoch X. Jiang, Arce Domingo-Relloso, Ahlam Abuawad, Karin Haack, Maria Tellez-Plaza, M. Danielle Fallin, Jason G. Umans, Lyle G. Best, Ying Zhang, Allison Kupsco, Daniel W. Belsky, Shelley A. Cole, Ana Navas-Acien
Journal: Environmental Health Perspectives (2023)

Inorganic arsenic (As) may increase the risk of cardiovascular disease (CVD) and all-cause mortality through accelerated aging, which can be estimated using epigenetic-based measures.
Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis
Authors: Wolfgang Merkt, Merle Freitag, Maren Claus, Philipp Kolb, Valeria Falcone, Manuel Röhrich, Lea Rodon, Franca Deicher, Ivana Andreeva, Theresa Tretter, Lars-Oliver Tykocinski, Norbert Blank, Carsten Watzl, Anita Schmitt, Tim Sauer, Carsten Müller-Tidow, Markus Polke, Claus Peter Heußel, Peter Dreger, Hanns-Martin Lorenz, Michael Schmitt
Journal: Annals of the Rheumatic Diseases (2023)

and further staff of the Medizinische Klinik V and Thoraxklinik, Heidelberg, including
Tofacitinib is Effective in Treating Refractory Immune Checkpoint Inhibitor Hepatitis
Authors: Mike Wang, Kerry L. Reynolds, Kamaneh Montazeri, Esperance A. Schaefer, Ryan J. Sullivan, Michael Dougan
Journal: Clinical Gastroenterology and Hepatology (2023)

Immune checkpoint inhibitors (ICI) have improved metastatic melanoma outcomes; however, toxicities, such as hepatitis, can be dose-limiting or even fatal.
ctDNA quantification improves estimation of outcomes in patients with high-grade osteosarcoma: a translational study from the OS2006 trial
Authors: B. Audinot, D. Drubay, N. Gaspar, A. Mohr, C. Cordero, P. Marec-Bérard, C. Lervat, S. Piperno-Neumann, M. Jimenez, L. Mansuy, M.-P. Castex, G. Revon-Riviere, A. Marie-Cardine, C. Berger, C. Piguet, K. Massau, B. Job, G. Moquin-Beaudry, M.-C. Le Deley, M.-D. Tabone, P. Berlanga, L. Brugières, B.D. Crompton, A. Marchais, S. Abbou
Journal: Annals of Oncology (2023)
Interleukin-15 and -21-activated, donor-derived NK cell infusion after haploidentical HCT in high-risk AML and MDS—a cohort analysis
Authors: Kyoo-Hyung Lee, Sewon Lee, Young Hoon Park, Yeung-Chul Mun, Eun-Ji Choi, Yunsuk Choi, Han-Seung Park, Jung-Hee Lee, Je-Hwan Lee, Soo-Yeon Park, Suk Ran Yoon, Inpyo Choi
Journal: Leukemia (2023)
Author Correction: Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial
Authors: Ken Mautner, Michael Gottschalk, Scott D. Boden, Alison Akard, Won C. Bae, Lora Black, Blake Boggess, Paramita Chatterjee, Christine B. Chung, Kirk A. Easley, Greg Gibson, Josh Hackel, Katie Jensen, Linda Kippner, Chad Kurtenbach, Joanne Kurtzberg, R. Amadeus Mason, Benjamin Noonan, Krishnendu Roy, Verle Valentine, Carolyn Yeago, Hicham Drissi
Journal: Nature Medicine (2023)
Author Correction: Financial incentives for COVID-19 vaccines in a rural low-resource setting: a cluster-randomized trial
Authors: Raymond Duch, Edward Asiedu, Ryota Nakamura, Thomas Rouyard, Alberto Mayol, Adrian Barnett, Laurence Roope, Mara Violato, Dorcas Sowah, Piotr Kotlarz, Philip Clarke
Journal: Nature Medicine (2023)
CPAP resumption after a first termination and impact on all-cause mortality in France
Authors: Jean-Louis Pépin, Renaud Tamisier, Adam V. Benjafield, Pierre Rinder, Florent Lavergne, Anne Josseran, Paul Sinel-Boucher, Peter A. Cistulli, Atul Malhotra, Pierre Hornus, Sébastien Bailly
Journal: European Respiratory Journal (2023)

Background Continuation of continuous positive airway pressure (CPAP) therapy after initial prescription has been shown to reduce all-cause mortality versus therapy termination. However, there is a lack of data on the rates and impact of resuming CPAP in patients with obstructive sleep apnoea (OSA). This analysis determined the prevalence of CPAP resumption in the year after termination, characterised determinants of CPAP resumption, and examined the impact of CPAP resumption on all-cause mortality. Methods French national health insurance reimbursement system data for adults aged ≥18 years were used. CPAP prescription was identified by specific treatment codes. Patients who resumed CPAP after first therapy termination and continued to use CPAP for 1 year were matched with those who resumed CPAP then terminated therapy for a second time. Results Out of 103 091 individuals with a first CPAP termination, 26% resumed CPAP over the next 12 months, and 65% of these were still using CPAP 1 year later. Significant predictors of CPAP continuation after resumption included male sex, hypertension and CPAP prescription by a pulmonologist. In the matched population, the risk of all-cause death was 38% lower in individuals who continued using CPAP after therapy resumption versus those who had a second therapy discontinuation (hazard ratio 0.62, 95% CI 0.48–0.79; p=0.0001). Conclusion These data suggest that individuals with OSA who fail initial therapy with CPAP should be offered a second trial with the device to ensure that effective therapy is not withheld from those who might benefit.
Real‐world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population
Authors: Edoardo Bertero, Chiara Chiti, Maria Alessandra Schiavo, Giacomo Tini, Paolo Costa, Giancarlo Todiere, Barbara Mabritto, Lorenzo‐Lupo Dei, Alessia Giannattasio, Davide Mariani, Carla Lofiego, Caterina Santolamazza, Emanuele Monda, Giovanni Quarta, Davide Barbisan, Giulia Elena Mandoli, Massimo Mapelli, Maurizio Sguazzotti, Francesco Negri, Simona De Vecchi, Michele Ciabatti, Daniela Tomasoni, Andrea Mazzanti, Francesca Marzo, Cesare de Gregorio, Claudia Raineri, Pier Filippo Vianello, Alberto Marchi, Giulia Biagioni, Eleonora Insinna, Vanda Parisi, Raffaello Ditaranto, Andrea Barison, Andrea Giammarresi, Gaetano Maria De Ferrari, Silvia Priori, Marco Metra, Maurizio Pieroni, Giuseppe Patti, Massimo Imazio, Enrica Perugini, Piergiuseppe Agostoni, Matteo Cameli, Marco Merlo, Gianfranco Sinagra, Michele Senni, Giuseppe Limongelli, Enrico Ammirati, Fabio Vagnarelli, Lia Crotti, Luigi Badano, Chiara Calore, Domenico Gabrielli, Federica Re, Giuseppe Musumeci, Michele Emdin, Emanuele Barbato, Beatrice Musumeci, Camillo Autore, Elena Biagini, Italo Porto, Iacopo Olivotto, Marco Canepa
Journal: European Journal of Heart Failure (2023)

Aims In the EXPLORER‐HCM trial, mavacamten reduced left ventricular outflow tract obstruction (LVOTO) and improved functional capacity of symptomatic hypertrophic obstructive cardiomyopathy (HOCM) patients. We sought to define the potential use of mavacamten by comparing real‐world HOCM patients with those enrolled in EXPLORER‐HCM and assessing their eligibility to treatment. Methods and results We collected information on HOCM patients followed up at 25 Italian HCM outpatient clinics and with significant LVOTO (i.e. gradient ≥30 mmHg at rest or ≥50 mmHg after Valsalva manoeuvre or exercise) despite pharmacological or non‐pharmacological therapy. Pharmacological or non‐pharmacological therapy resolved LVOTO in 1044 (61.2%) of the 1706 HOCM patients under active follow‐up, whereas 662 patients (38.8%) had persistent LVOTO. Compared to the EXPLORER‐HCM trial population, these real‐world HOCM patients were older (62.1 ± 14.3 vs. 58.5 ± 12.2 years, p = 0.02), had a lower body mass index (26.8 ± 5.3 vs. 29.7 ± 4.9 kg/m 2 , p &lt; 0.0001) and a more frequent history of atrial fibrillation (21.5% vs. 9.8%, p = 0.027). At echocardiography, they had lower left ventricular ejection fraction (LVEF, 66 ± 7% vs. 74 ± 6%, p &lt; 0.0001), higher left ventricular outflow tract gradients at rest (60 ± 27 vs. 52 ± 29 mmHg, p = 0.003), and larger left atrial volume index (49 ± 16 vs. 40 ± 12 ml/m 2 , p &lt; 0.0001). Overall, 324 (48.9%) would have been eligible for enrolment in the EXPLORER‐HCM trial and 339 (51.2%) for treatment with mavacamten according to European guidelines. Conclusions Real‐world HOCM patients differ from the EXPLORER‐HCM population for their older age, lower LVEF and larger atrial volume, potentially reflecting a more advanced stage of the disease. About half of real‐world HOCM patients were found eligible to mavacamten.
Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of <scp>SAVOR‐TIMI</scp> 53, <scp>DECLARE‐TIMI</scp> 58 and <scp>CAMELLIA‐TIMI</scp> 61
Authors: Siddharth M. Patel, David A. Morrow, Andrea Bellavia, David D. Berg, Deepak L. Bhatt, Petr Jarolim, Lawrence A. Leiter, Darren K. McGuire, Itamar Raz, P. Gabriel Steg, John P.H. Wilding, Marc S. Sabatine, Stephen D. Wiviott, Eugene Braunwald, Benjamin M. Scirica, Erin A. Bohula
Journal: European Journal of Heart Failure (2023)
In Vivo Silencing of Regulatory Elements Using a Single AAV-CRISPRi Vector
Authors: P. Laurette, C. Cao, D. Ramanujam, M. Schwaderer, T. Lueneburg, S. Kuss, L. Weiss, R. Dilshat, E.E.M. Furlong, F. Rezende, S. Engelhardt, R. Gilsbach
Journal: Circulation Research (2023)
Association of Combined <scp>Anti‐Ro52</scp>/<scp>TRIM21</scp> and <scp>Anti‐Ro60</scp>/<scp>SSA</scp> Antibodies With Increased Sjögren Disease Severity Through Interferon Pathway Activation
Authors: Eléonore Bettacchioli, Alain Saraux, Alice Tison, Divi Cornec, Maryvonne Dueymes, Nathan Foulquier, Sophie Hillion, Anne‐Marie Roguedas‐Contios, Anas‐Alexis Benyoussef, Marta E. Alarcon‐Riquelme, Jacques‐Olivier Pers, Valérie Devauchelle‐Pensec
Journal: Arthritis & Rheumatology (2023)

Objective The biologic diagnosis of primary Sjögren disease (SjD) mainly relies on anti‐Ro60/SSA antibodies, whereas the significance of anti‐Ro52/TRIM21 antibodies currently remains unclear. The aim of this study was to characterize the clinical, serological, biologic, transcriptomic, and interferon profiles of patients with SjD according to their anti‐Ro52/TRIM21 antibody status. Methods Patients with SjD from the European PRECISESADS (n = 376) and the Brittany Diagnostic Suspicion of primitive Sjögren's Syndrome (DIApSS); (n = 146) cohorts were divided into four groups: double negative (Ro52 − /Ro60 − ), isolated anti‐Ro52/TRIM21 positive (Ro52 + ), isolated anti‐Ro60/SSA positive (Ro60 + ), and double‐positive (Ro52 + /Ro60 + ) patients. Clinical information; EULAR Sjögren Syndrome Disease Activity Index, a score representing systemic activity; and biologic markers associated with disease severity were evaluated. Transcriptome data obtained from whole blood by RNA sequencing and type I and II interferon signatures were analyzed for PRECISESADS patients. Results In the DIApSS cohort, Ro52 + /Ro60 + patients showed significantly more parotidomegaly (33.3% vs 0%–11%) along with higher β2‐microglobulin ( P = 0.0002), total immunoglobulin ( P &lt; 0.0001), and erythrocyte sedimentation rate levels ( P = 0.002) as well as rheumatoid factor (RF) positivity (66.2% vs 20.8%–25%) compared to other groups. The PRECISESADS cohort corroborated these observations, with increased arthritis ( P = 0.046), inflammation ( P = 0.005), hypergammaglobulinemia ( P &lt; 0.0001), positive RF ( P &lt; 0.0001), leukopenia ( P = 0.004), and lymphopenia ( P = 0.009) in Ro52 + /Ro60 + patients. Cumulative EULAR Sjögren Syndrome Disease Activity Index results further confirmed these disparities ( P = 0.002). Transcriptome analysis linked anti‐Ro52/TRIM21 antibody positivity to interferon pathway activation as an underlying cause for these clinical correlations. Conclusion These results suggest that the combination of anti‐Ro52/TRIM21 and anti‐Ro60/SSA antibodies is associated with a clinical, biologic, and transcriptional profile linked to greater disease severity in SjD through the potentiation of the interferon pathway activation by anti‐Ro52/TRIM21 antibodies. image
Ultrahigh‐Efficacy VEGF Neutralization Using Carbonized Nanodonuts: Implications for Intraocular Anti‐Angiogenic Therapy
Authors: Hong‐Jyuan Jian, Anisha Anand, Jui‐Yang Lai, Chih‐Ching Huang, David Hui‐Kang Ma, Chi‐Chun Lai, Huan‐Tsung Chang
Journal: Advanced Healthcare Materials (2023)

Abstract Ocular angiogenesis, associated with diseases such as retinopathy of prematurity and diabetic retinopathy, is a leading cause of irreversible vision loss. Herein, carbon nanodonuts (CNDs) with a donut‐shaped structure are synthesized using sodium alginate (SA) and 1,8‐diaminooctane (DAO) through a one‐step thermal process. The formation of SA/DAO‐CNDs occurs through a crosslinking reaction between SA and DAO, creating amide bonds followed by partial carbonization. In human retinal pigment epithelial cells exposed to H 2 O 2 or lipopolysaccharide, the SA/DAO‐CNDs display a more than fivefold reduction in reactive oxygen species and proinflammatory cytokines, such as IL‐6 and IL‐1β, when compared to carbonized nanomaterials produced exclusively from SA. Furthermore, the CNDs effectively inhibit vascular endothelial growth factor A‐165 (VEGF‐A 165 )‐induced cell migration and tube formation in human umbilical vein endothelial cells due to their strong affinity for VEGF‐A 165 , with a dissociation constant of 2.2 × 10 −14 M , over 1600 times stronger than the commercial drug bevacizumab (Avastin). Trypsin digestion coupled with LC‐MS/MS analysis reveals that VEGF‐A 165 interacts with SA/DAO‐CNDs through its heparin‐binding domain, leading to activity loss. The SA/DAO‐CNDs demonstrate excellent biocompatibility and potent anti‐angiogenic effects in chicken embryos and rabbit eyes. These findings suggest that SA/DAO‐CNDs hold promise as a therapeutic agent for treating various angiogenesis‐related ocular diseases.
Commentary on oncolytic viruses: past, present, and future
Authors: Christopher Larson, Bryan Oronsky, Tony R Reid
Journal: Journal for ImmunoTherapy of Cancer (2023)

Whither oncolytic viruses? From the peak of their popularity in the early 2000s, when the ONYX-015 adenovirus had just entered the clinic, and then again in 2015 when the Food and Drug Administration-approved talimogene laherparepvec (also known as OncoVEX